We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RGS:NASDAQRegis Corporation Analysis

Data as of 2026-07-03 - not real-time

$27.10

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Regis Corporation trades at $27.1, comfortably above its immediate support of $26.04 but below both the 20‑day SMA ($27.24) and 50‑day SMA ($27.55), indicating a modest short‑term pull‑back. The MACD histogram has turned positive (0.014) while the MACD signal is bullish, and the RSI sits near 48, suggesting neutral momentum with room for a modest upside. Valuation metrics are strikingly cheap – a trailing PE of 0.6, price‑to‑book of 0.36 and price‑to‑sales of 0.30 – positioning the stock as *significantly undervalued* relative to its book value of $75.8 per share. Despite a high ROE of 94% and a profit margin above 50%, revenue is contracting (-8%) and the balance sheet is leveraged, with debt of $312 M and a debt‑to‑equity ratio exceeding 160. The market’s sentiment is extremely bullish (Fear & Greed Index 92.96, “Extreme Greed”), yet the 30‑day volatility of 28% and a low average daily volume signal heightened price swings and limited liquidity.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price hovering just above the identified support level
  • Bullish MACD crossover with a modest histogram gain
  • Neutral RSI indicating limited upside momentum

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Deep valuation discounts (PE 0.6, PB 0.36) relative to book value
  • Upside potential of ~55% versus the median target price of $42
  • Strong ROE and profit margin suggesting operational efficiency

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • Franchise‑heavy business model offering scalability
  • Industry recovery prospects for personal services post‑economic cycle
  • Balance‑sheet concerns (high debt) tempered by cash generation and low beta

Key Metrics & Analysis

Financial Health

Revenue Growth-8.00%
Profit Margin52.01%
P/E Ratio0.6
ROE93.71%
ROA2.78%
Debt/Equity164.92
P/B Ratio0.4
Op. Cash Flow$15.7M
Free Cash Flow$8.6M

Technical Analysis

TrendNeutral
RSI48.0
Support$26.04
Resistance$28.50
MA 20$27.24
MA 50$27.55
MA 200$26.52
MACDBullish
VolumeStable
Fear & Greed Index92.96

Valuation

Target Price$42.00
Upside/Downside54.98%
GradeUndervalued
TypeValue

Risk Assessment

Beta0.69
Volatility28.17%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.